牛牛AI助理已提取核心訊息
On December 29, 2023, a Schedule 13G filing was made with the United States Securities and Exchange Commission (SEC) by The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC, indicating a significant investment in bluebird bio, Inc. The filing revealed that Goldman Sachs collectively owns 12,181,040 shares of bluebird bio, which represents approximately 0.4% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b), which is typically used by passive investors to report holdings. The address for both The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC is 200 West Street, New York, NY. The filing included a certification that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect.
On December 29, 2023, a Schedule 13G filing was made with the United States Securities and Exchange Commission (SEC) by The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC, indicating a significant investment in bluebird bio, Inc. The filing revealed that Goldman Sachs collectively owns 12,181,040 shares of bluebird bio, which represents approximately 0.4% of the company's common stock. The shares are held with shared voting and dispositive power. The filing was made under Rule 13d-1(b), which is typically used by passive investors to report holdings. The address for both The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC is 200 West Street, New York, NY. The filing included a certification that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect.
2023年12月29日，高盛集團及其子公司高盛公司向美國證券交易委員會（SEC）提交了附表13G申報。有限責任公司表示對藍鳥生物公司進行了大量投資。該文件顯示，高盛共擁有藍鳥生物的12,181,040股股份，約佔該公司普通股的0.4％。這些股份以共同的投票權和處置權持有。該申報是根據規則13d-1（b）提交的，被動投資者通常使用該規則來報告持股情況。高盛集團和高盛公司的地址有限責任公司位於紐約州紐約西街 200 號。該文件包括一份證明，證明這些股票是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權，也不是與具有這種目的或效果的任何交易有關。
2023年12月29日，高盛集團及其子公司高盛公司向美國證券交易委員會（SEC）提交了附表13G申報。有限責任公司表示對藍鳥生物公司進行了大量投資。該文件顯示，高盛共擁有藍鳥生物的12,181,040股股份，約佔該公司普通股的0.4％。這些股份以共同的投票權和處置權持有。該申報是根據規則13d-1（b）提交的，被動投資者通常使用該規則來報告持股情況。高盛集團和高盛公司的地址有限責任公司位於紐約州紐約西街 200 號。該文件包括一份證明，證明這些股票是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權，也不是與具有這種目的或效果的任何交易有關。
有用
沒用